SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (9241)5/17/2002 1:11:59 AM
From: ewolf  Respond to of 9719
 
Speaking of patience--I'm wondering if you understand the appeal process that corixa is undertaking. On what basis would Corixa be granted an appeal from the fda that has consistently rejected bexxar as a viable drug. Is this the same avenue that lcbm followed with success? It sounds as if the resolution process begins with a decision as to whether the disagreement even merits resolution. Is that right? I'd appreciate any information. Thanks, eaw



To: Vector1 who wrote (9241)5/17/2002 1:28:11 PM
From: ewolf  Read Replies (1) | Respond to of 9719
 
I suppose I found the answer to my question here: www.fda.gov/cber/gdlns/dispute.pdf If you're interested or know anything else I'd appreciate the input. Thanks, eaw


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News